Bimagrumab (BYM338) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
Purity:
>98.0%
CAS Number:
[1356922-05-8]
Target:
TGF-beta/Smad
* VAT and and shipping costs not included. Errors and price changes excepted